Introduction As one of the most active innovative drug development areas at present, Antibody-Drug Conjugates (ADCs) are rising at an astonishing pace. The global industry interest continues to heat up, with ADC innovative drugs being approved one after another. As of March 2025, a total of 17 ADC products have been approved for market release … Read more
Follow Xiaobai Learning Medicine As of now, 17 ADC drugs have been approved worldwide, of which 5 ADCs are coupled with lysine. Table 1 Summary of ADC Drugs Coupled with Lysine Approved Product Name Company Target DAR Toxin Linker Antibody Type Payload Type Mylotarg Pfizer CD33 2~3 Calicheamicin Hydrazone Link (Acid-labile) IG4 DNA Damaging Agent … Read more
The AACR is always bustling every year, and this year I am particularly focused on the progress of dual payload ADCs. I have written several articles on this topic before, and just a few days ago, I was discussing with my supervisor that “I haven’t seen any dual payload ADCs advancing to clinical trials yet,” … Read more
If a few years ago, presenting a simple PowerPoint on the ADC field could impress without the need for future visions, cutting-edge technologies, or a vibrant pipeline forest, today, the ADC field requires substantial content to make an impact. This shift is attributed to advancements in industry technology and rising awareness. Data shows that from … Read more
After 2019, ADC drugs have been approved for marketing one after another, and the approval of Aidiqi in 2021 marked a milestone in the development of domestic ADC innovative drugs. The broad therapeutic prospects and huge market size have stimulated many pharmaceutical companies to ignite their enthusiasm for ADC drug research and development, leading the … Read more
Introduction Antibodies are one of the key components of ADC drugs, serving as precise guiding components with the functions of targeting and toxin delivery. They can specifically recognize the target antigens on the surface of tumor cells, delivering toxins to the tumor cells and mediating the localization and endocytosis of ADCs in tumor cells[1]. After … Read more
GUIDE Editor’s Recommendation Antibody-drug conjugates (ADC) remained popular in 2022. Enhertu redefined the treatment landscape for HER2 breast cancer, making headlines at major academic conferences like ASCO and ESMO; Kelun-Biotech approached a $10 billion license-out deal with multinational pharmaceutical company Merck, setting a new record for local pharmaceutical companies going abroad; the world’s first anti-CD79b … Read more
Protein Hydrolysis Targeted Chimeras (PROTAC) are bringing revolutionary changes to the fields of biology and medicinal chemistry. PROTAC consists of a target protein ligand, an E3 ligase ligand, and a spacer group[Unlike the linker used in antibody-drug conjugates, here we specifically use “spacer” instead of the commonly seen “linker” in PROTAC literature]. PROTAC structural composition … Read more
To deliver chemotherapy drugs more effectively, small molecule drug conjugates (SMDC), antibody-drug conjugates (ADC), and degrader-antibody conjugates (DAC) have been explored and developed, providing selective delivery while improving the therapeutic index. What are their similarities and differences? What are their respective advantages? What is the current state of research? What does the future hold? This … Read more
Recently, ADC (Antibody-Drug Conjugate) conferences have been held one after another, with major biotech companies competing to report their ADC pipelines. It is expected that 2024 will still be the main venue for ADCs. Developing an entry-level ADC seems not difficult, but evaluating the pharmacology and toxicology in the preclinical stage has become a top … Read more